ABPI

Market Access

Industry exercises option for midpoint review of VPAG Invest...

Under the VPAG agreement, £400 million is available under the VPAG Investment Fund. But what benefits will stay once funding goes away in 2029?

Market Access

Health, growth & renewal: ABPI 2026 looks to UK’s future

The Association of the British Pharmaceutical Industry (ABPI)'s flagship annual conference took place on Thursday, 23rd April.

Market Access

The companies shaping the UK’s commercial landscape

Which companies are working with the government to implement the US-UK pharmaceutical trade agreement?

News

UK says it has hit target on commercial trial set-up times

The UK has made progress in its efforts to slash set-up times for clinical trials, one of the factors blamed for a decline in industry-backed studies.

Market Access

Metrics discussion around boardroom table

Highlights from the UK’s December 2025 VPAG metrics

Leela Barham looked at the latest metrics used to monitor the UK’s voluntary pricing scheme.

News

NHS risks missing out on independent prescriber benefits

Gaps in support could undermine a wave of new independent prescribers entering the NHS and a push for more community-based care, warns a new report.

Industry exercises option for midpoint review of VPAG Invest...

Health, growth & renewal: ABPI 2026 looks to UK’s future

The companies shaping the UK’s commercial landscape

UK says it has hit target on commercial trial set-up times

Highlights from the UK’s December 2025 VPAG metrics

NHS risks missing out on independent prescriber benefits

ASCO 2026: Powerful evidence for the microbiome in oncology,...

Discover a new era of healthcare panel engagement: Grounded ...

ABPI

Editor's Picks